Head of International Markets & Business Affairs, Member of the Management BoardContact us
The Basel-based pharmaceutical company Urovant has appointed Keith A. Katkin as its new CEO. With extensive experience in the pharmaceutical industry, he aims to advance the development of the lead candidate vibegron, which was developed to treat overactive bladder.
Urovant is a subsidiary of Roivant Sciences, a Basel-based pharmaceutical, and focuses on developing novel therapies for urologic conditions within the Roivant family of companies. BaselArea.swiss assisted Roivant and its subsidiaries relocate to Basel.
“I am excited to build Urovant into a leading company in the field of urology,” Katkin said in a statement announcing his appointment.
The new CEO served as president and CEO of the California-based Avanir Pharmaceuticals from 2007 to 2016, where he oversaw the company’s sale to Otsuka Pharmaceutical. Prior to that he was vice president at Peninsula Pharmaceuticals.
“I’d like to extend a warm welcome to Keith,” said Vivek Ramaswamy, founder and CEO of Roivant Sciences. “His track record of building successful companies and his passion for delivering new medicines to patients makes me excited to see him take charge as the leader of one of our newest Vants.”
Urovant’s lead therapeutic candidate is vibegron, which is being developed for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency.
Katkin describes the Phase 2 and Phase 3 data on vibegron as “promising”, adding: “I look forward to rapidly advancing the development of vibegron including the initiation of a confirmatory Phase 3 pivotal trial in the months to come.”